In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Northwest Biotherapeutics, Inc.

http://www.nwbio.com/

Latest From Northwest Biotherapeutics, Inc.

Finance Watch: VC Mega-Rounds Make A Comeback In March

Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.

Financing Innovation

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Deal Watch Business Strategies

Dealmaking Quarterly Statistics, Q4 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Deals Market Intelligence

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • NW Bio
UsernamePublicRestriction

Register